IPHA
Innate Pharma
IPHA
IPHA
13 hedge funds and large institutions have $2.58M invested in Innate Pharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Holders
13
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$386K | |
| 2 | +$8K | |
| 3 | +$7K | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5K |
| 5 |
Morgan Stanley
New York
|
+$4.45K |
Top Sellers
| 1 | -$282K | |
| 2 | -$127K | |
| 3 | -$29K | |
| 4 |
Millennium Management
New York
|
-$22.5K |
| 5 |
BlackRock
New York
|
-$19.3K |